iGenentech
Aug 11, 2020
FDA’s Ok to Roche’s Oral SMA Therapy; Roche’s Etrolizumab Mixed Results in Ulcerative Colitis; Secura receives rights to Copiktra from Verastem
Roche Set to Compete With Biogen and Novartis in the SMA Market With its First Oral Therapy The US FDA has recommended the use of Evrysdi (risdiplam), a candidate of Genentech, a Roche company, for spinal muscular atrophy (SMA), an inherited neuromuscular disease resulting in muscle atrophy, in adults and...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
